Affiliation:
1. Infectious Disease Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285
Abstract
ABSTRACT
Described here are the development and validation of a novel approach to identify genes encoding drug targets in
Streptococcus pneumoniae
. The method relies on the use of an ordered genomic library composed of PCR amplicons that were generated under error-prone conditions so as to introduce random mutations into the DNA. Since some of the mutations occur in drug target-encoding genes and subsequently affect the binding of the drug to its respective cellular target, amplicons containing drug targets can be identified as those producing drug-resistant colonies when transformed into
S. pneumoniae
. Examination of the genetic content of the amplicon giving resistance coupled with bioinformatics and additional genetic approaches could be used to rapidly identify candidate drug target genes. The utility of this approach was verified by using a number of known antibiotics. For drugs with single protein targets, amplicons were identified that rendered
S. pneumoniae
drug resistant. Assessment of amplicon composition revealed that each of the relevant amplicons contained the gene encoding the known target for the particular drug tested. Fusidic acid-resistant mutants that resulted from the transformation of
S. pneumoniae
with amplicons containing
fusA
were further characterized by sequence analysis. A single mutation was found to occur in a region of the
S. pneumoniae
elongation factor G protein that is analogous to that already implicated in other bacteria as being associated with fusidic acid resistance. Thus, in addition to facilitating the identification of genes encoding drug targets, this method could provide strains that aid future mechanistic studies.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference25 articles.
1. Cariello, N. F., J. A. Swenberg, A. De Bellis, and T. R. Skopek. 1991. Analysis of mutations using PCR and denaturing gradient gel electrophoresis. Environ. Mol. Mutagen.18:249-254.
2. Doern, G. V., A. B. Brueggemann, H. Huynh, and E. Wingert. 1999. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98. Emerg. Infect. Dis.5:757-765.
3. Don, R. H., P. T. Cox, B. J. Wainwright, K. Baker, and J. S. Mattick. 1991. "Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res.19:4008.
4. Dopazo, J., A. Mendoza, J. Herrero, F. Caldara, Y. Humbert, L. Friedli, M. Guerrier, E. Grand-Schenk, C. Gandin, M. De Francesco, A. Polissi, G. Buell, G. Feger, E. García, M. Peitsch, and J. F. García-Bustos. 2001. Annotated draft sequence from a Streptococcus pneumoniae type 19F clinical isolate. Microb. Drug Res.7:99-125.
5. Enright M. P. Zawadski P. Pickerill and C. G. Dowdson. 2000. Molecular evolution of rifampicin resistance in Streptococcus pneumoniae p. 427-432. In A. Tomasz (ed.) Streptococcus pneumoniae : molecular biology and mechanism of disease. Mary Ann Liebert Inc. Larchmont N.Y.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献